董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Buckman | 男 | Chairman of the Board | 65 | 2.42万美元 | 未持股 | 2020-12-31 |
| Jeff Ross | 男 | Chief Executive Officer and Director | 45 | 32.35万美元 | 未持股 | 2020-12-31 |
| John Erb | 男 | Director | 71 | 2.42万美元 | 未持股 | 2020-12-31 |
| Peter Maag | 男 | Director | 54 | 未披露 | 未持股 | 2020-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeff Ross | 男 | Chief Executive Officer and Director | 45 | 32.35万美元 | 未持股 | 2020-12-31 |
| Brian Niebur | 男 | Chief Financial Officer | 57 | 17.88万美元 | 未持股 | 2020-12-31 |
| Laji Kattungal | 男 | Vice President of Quality | 50 | 19.80万美元 | 未持股 | 2020-12-31 |
董事简历
中英对照 | 中文 | 英文- Paul Buckman
-
Paul Buckman目前是LivaNova PLC TMVR的总经理。在加入Livanova之前，Buckman先生于2013年9月至2017年3月担任Conventus Orthopaedics（一家位于明尼苏达州的公司，专门从事关节周围骨折固定）的首席执行官。Buckman从2012年2月到2013年9月担任SentreHeart，Inc.（一家医疗技术公司，专注于关闭各种解剖结构）首席执行官。此前，Buckman从2008年9月到2012年2月担任Pathway Medical Technologies，Inc.（一家医疗设备公司，专注于治疗外周动脉疾病）首席执行官和董事长；2006年12月至2008年9月；2004年8月至2006年12月，担任上市多元化医疗产品公司圣犹达医疗公司心脏病部总裁；以及EV3LLC董事会主席兼首席执行官，从2001年1月到2004年1月，Buckman先生创立了一家总部位于明尼苏达州的医疗器械公司，专注于血管内疗法，并将其发展成为一家价值8000万美元的企业。巴克曼先生在医疗设备行业工作了30多年，包括在SCIMED Life Systems，Inc.和波士顿科学国际有限公司（一家公开上市的医疗设备制造商）工作了10年，在那里他担任过几个执行职位，直到2000年1月成为波士顿科学公司心脏病部门的总裁。Buckman先生目前还担任NeuroOne，Inc.的董事。Chariman，Ablative Solutions，Inc.，Activortho，Aortica，Inc.，Dyamx，Inc.和MiroMatrix，Inc.（董事长）。他此前曾担任Conventus Orthopaedics公司、Caisson Interventional LLC、Velocimed公司的董事，在那里他曾担任Endicor公司、Microvena公司、Sunshine Heart公司（上市早期医疗设备公司）、Micro Therapeutics公司的联席创始人。除了筹集了超过5亿美元的私人资本外，巴克曼担任首席执行官、董事或联合创始人的公司的总退出价值约为28亿美元。Buckman先生在西密歇根大学（Western Michigan University）获得工商管理与财务硕士学位和工商管理学士学位。
Paul Buckman,has served as Chief Executive Officer of Rhythmlink International LLC. Mr. Buckman previously served as President of Advanced Circulatory Support for LivaNova PLC (Nasdaq: LIVN) and as President, North America and the general manager of structural heart for LivaNova PLC beginning in April 2017. Prior to joining LivaNova PLC, Mr. Buckman served as chief executive officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation, from September 2013 until March of 2017. Mr. Buckman was chief executive officer of Sentreheart, Inc., a medical technology company focused on closure of various anatomic structures, from February 2012 to September 2013. Previously, Mr. Buckman served as chief executive officer and chairman of Pathway Medical Technologies, Inc., a medical device company focused on treatment of peripheral arterial disease, from September 2008 to February 2012; as chief executive officer of Devax, Inc., a developer and manufacturer of drug eluting stents, from December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc., a publicly traded diversified medical products company, from August 2004 to December 2006; and as chairman of the board of directors and chief executive officer of ev3, LLC, a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman founded and developed into an $80 million business, from January 2001 to January 2004. Mr. Buckman has worked in the medical device industry for over 30 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation (NYSE: BSX), a publicly traded medical device manufacturer, where he held several executive positions before becoming president of the cardiology division of Boston Scientific in January 2000. Mr. Buckman also currently serves as a director for Helius Medical Technologies Corporation (Nasdaq: HSDT), Ablative Solutions, Inc., ActivOrtho Inc., a privately held company, Shoulder Innovations, Inc., a privately held company, Rhythmlink International LLC, a privately held company, and as chairman of Miromatrix, Inc. He previously served as a director of Aortica, Inc., DyaMX, Inc., Conventus Orthopaedics, Caisson Interventional LLC, Velocimed, Inc., where he was a co-founder, EndiCor, Inc., Microvena, Inc., Sunshine Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company, NexGen Medical, and Micro Therapeutics, Inc. Mr. Buckman received a Master's degree in Business Administration and Finance and a B.A. degree in Business Administration from Western Michigan University. - Paul Buckman目前是LivaNova PLC TMVR的总经理。在加入Livanova之前，Buckman先生于2013年9月至2017年3月担任Conventus Orthopaedics（一家位于明尼苏达州的公司，专门从事关节周围骨折固定）的首席执行官。Buckman从2012年2月到2013年9月担任SentreHeart，Inc.（一家医疗技术公司，专注于关闭各种解剖结构）首席执行官。此前，Buckman从2008年9月到2012年2月担任Pathway Medical Technologies，Inc.（一家医疗设备公司，专注于治疗外周动脉疾病）首席执行官和董事长；2006年12月至2008年9月；2004年8月至2006年12月，担任上市多元化医疗产品公司圣犹达医疗公司心脏病部总裁；以及EV3LLC董事会主席兼首席执行官，从2001年1月到2004年1月，Buckman先生创立了一家总部位于明尼苏达州的医疗器械公司，专注于血管内疗法，并将其发展成为一家价值8000万美元的企业。巴克曼先生在医疗设备行业工作了30多年，包括在SCIMED Life Systems，Inc.和波士顿科学国际有限公司（一家公开上市的医疗设备制造商）工作了10年，在那里他担任过几个执行职位，直到2000年1月成为波士顿科学公司心脏病部门的总裁。Buckman先生目前还担任NeuroOne，Inc.的董事。Chariman，Ablative Solutions，Inc.，Activortho，Aortica，Inc.，Dyamx，Inc.和MiroMatrix，Inc.（董事长）。他此前曾担任Conventus Orthopaedics公司、Caisson Interventional LLC、Velocimed公司的董事，在那里他曾担任Endicor公司、Microvena公司、Sunshine Heart公司（上市早期医疗设备公司）、Micro Therapeutics公司的联席创始人。除了筹集了超过5亿美元的私人资本外，巴克曼担任首席执行官、董事或联合创始人的公司的总退出价值约为28亿美元。Buckman先生在西密歇根大学（Western Michigan University）获得工商管理与财务硕士学位和工商管理学士学位。
- Paul Buckman,has served as Chief Executive Officer of Rhythmlink International LLC. Mr. Buckman previously served as President of Advanced Circulatory Support for LivaNova PLC (Nasdaq: LIVN) and as President, North America and the general manager of structural heart for LivaNova PLC beginning in April 2017. Prior to joining LivaNova PLC, Mr. Buckman served as chief executive officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation, from September 2013 until March of 2017. Mr. Buckman was chief executive officer of Sentreheart, Inc., a medical technology company focused on closure of various anatomic structures, from February 2012 to September 2013. Previously, Mr. Buckman served as chief executive officer and chairman of Pathway Medical Technologies, Inc., a medical device company focused on treatment of peripheral arterial disease, from September 2008 to February 2012; as chief executive officer of Devax, Inc., a developer and manufacturer of drug eluting stents, from December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc., a publicly traded diversified medical products company, from August 2004 to December 2006; and as chairman of the board of directors and chief executive officer of ev3, LLC, a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman founded and developed into an $80 million business, from January 2001 to January 2004. Mr. Buckman has worked in the medical device industry for over 30 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation (NYSE: BSX), a publicly traded medical device manufacturer, where he held several executive positions before becoming president of the cardiology division of Boston Scientific in January 2000. Mr. Buckman also currently serves as a director for Helius Medical Technologies Corporation (Nasdaq: HSDT), Ablative Solutions, Inc., ActivOrtho Inc., a privately held company, Shoulder Innovations, Inc., a privately held company, Rhythmlink International LLC, a privately held company, and as chairman of Miromatrix, Inc. He previously served as a director of Aortica, Inc., DyaMX, Inc., Conventus Orthopaedics, Caisson Interventional LLC, Velocimed, Inc., where he was a co-founder, EndiCor, Inc., Microvena, Inc., Sunshine Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company, NexGen Medical, and Micro Therapeutics, Inc. Mr. Buckman received a Master's degree in Business Administration and Finance and a B.A. degree in Business Administration from Western Michigan University.
- Jeff Ross
-
杰夫·罗斯（Jeff Ross）自2017年起担任我们的首席执行官，并自2019年10月起担任董事会成员。在担任我们的首席执行官之前，Ross博士于2010年至2017年担任我们的产品开发副总裁。Ross博士在Guidant开始了他的行业生涯，领导着一个新心血管疗法的生物制剂小组。跟随Guidant，他在Athersys工作，协助干细胞技术的商业化和扩展。他随后在SurModics担任生物制剂研究和商业开发总监。Ross博士拥有30多项已发表和发布的专利，以及《自然》和《临床研究杂志》的领先出版物。他拥有明尼苏达大学的生物医学工程硕士学位和分子，细胞和发育生物学博士学位。
Jeff Ross has been our Chief Executive Officer since 2017 and has served on our Board since October of 2019. Prior to serving as our Chief Executive Officer, Dr. Ross was our Vice President of Product Development from 2010 to 2017. Dr. Ross started his industry career at Guidant leading a biologics group for new cardiovascular therapies. Following Guidant, he worked at Athersys assisting with the commercialization and scale up of stem cell technologies. He then served as Director of Research and Commercial Development of Biologics at SurModics. Dr. Ross has over 30 published and issued patents along with leading publications in Nature and the Journal of Clinical Investigation. He holds a M.S. in Biomedical Engineering and a Ph.D. in Molecular, Cellular and Developmental Biology, from the University of Minnesota. - 杰夫·罗斯（Jeff Ross）自2017年起担任我们的首席执行官，并自2019年10月起担任董事会成员。在担任我们的首席执行官之前，Ross博士于2010年至2017年担任我们的产品开发副总裁。Ross博士在Guidant开始了他的行业生涯，领导着一个新心血管疗法的生物制剂小组。跟随Guidant，他在Athersys工作，协助干细胞技术的商业化和扩展。他随后在SurModics担任生物制剂研究和商业开发总监。Ross博士拥有30多项已发表和发布的专利，以及《自然》和《临床研究杂志》的领先出版物。他拥有明尼苏达大学的生物医学工程硕士学位和分子，细胞和发育生物学博士学位。
- Jeff Ross has been our Chief Executive Officer since 2017 and has served on our Board since October of 2019. Prior to serving as our Chief Executive Officer, Dr. Ross was our Vice President of Product Development from 2010 to 2017. Dr. Ross started his industry career at Guidant leading a biologics group for new cardiovascular therapies. Following Guidant, he worked at Athersys assisting with the commercialization and scale up of stem cell technologies. He then served as Director of Research and Commercial Development of Biologics at SurModics. Dr. Ross has over 30 published and issued patents along with leading publications in Nature and the Journal of Clinical Investigation. He holds a M.S. in Biomedical Engineering and a Ph.D. in Molecular, Cellular and Developmental Biology, from the University of Minnesota.
- John Erb
-
John Erb先生，自2002年10月是我公司公司董事会成员后，于2011年5担任公司董事会主席。Erb先生在医疗器械行业拥有超过30年的经验。Erb先生自2007年2月起，担任Cardia Access, Inc.公司的首席执行官，这是一家涉及对心脏疾病的治疗及开发新设备的医疗设备公司。2007年间，Erb先生担任CHF Solutions公司董事会执行主席。这是一家参与开发，制造治疗充血性心脏衰竭设备，并且负责分配的一家医疗器械公司。从2001年到2006年公司Erb先生担任CHF Solutions首席执行官。Erb先生从1997年开始在IntraTherapeutics公司担任裁兼首席执行官公司直到2001年该公司被Sulzer Medica 收购。该公司是一家参与末梢血管支架的研发，生产和销售的医疗器械公司。此前，Erb先生是在 Pfizer公司的一个部门--施耐德全球运营任职副总裁。他从2001年10月开始是SenoRx这家上市公司的董事，直到这家公司被C. R. Bard公司于2010年7月收购。同时在2000年10月，他在CryoCath Technologies这家加拿大上市公司任职董事，直到这家公司在2008年12月被收购。Erb先生目前是Sunshine Heart公司、 Osprey医疗公司以及其他几个私人公司的董事。
John Erb has served on our Board since April of 2017. Mr. Erb is currently Chairman of the Board for Nuwellis Inc., a global medical device company involved in the treatment of heart failure, and has been in that role since 2016. He also currently serves as Chairman of the Board of Directors for Osprey Medical, a public ASX company. Mr. Erb is co-founder of NuAx, Inc. formerly Cardia Access, Inc., a medical device company involved in developing new devices for the treatment of heart disease. Previously, Mr. Erb served as Chairman of the Board of Directors for Vascular Solution, Inc., a public NASDAQ company, (acquired by Teleflex Incorporated), and was a board member for CryoCath Technologies (acquired by Medtronic in 2008) and SenoRx, Inc. (acquired by CR Bard in 2010). From 2001 through 2006 Mr. Erb was Chief Executive Officer of CHF Solutions, Inc., a medical device company focused on the treatment of congestive heart failure. CHF Solutions, Inc. was acquired by Gambro. From 1997 through 2001 Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents. IntraTherapeutics, Inc. was acquired by Sulzer Medica. Other previous executive experience includes Vice President of Operations for Schneider Worldwide, a division of Pfizer, Inc.; ten years with Johnson & Johnson’s Iolab Division; and the start of his career with American Hospital Supply Corporation. Mr. Erb has a B.S. in Business Administration from California State University, Fullerton. - John Erb先生，自2002年10月是我公司公司董事会成员后，于2011年5担任公司董事会主席。Erb先生在医疗器械行业拥有超过30年的经验。Erb先生自2007年2月起，担任Cardia Access, Inc.公司的首席执行官，这是一家涉及对心脏疾病的治疗及开发新设备的医疗设备公司。2007年间，Erb先生担任CHF Solutions公司董事会执行主席。这是一家参与开发，制造治疗充血性心脏衰竭设备，并且负责分配的一家医疗器械公司。从2001年到2006年公司Erb先生担任CHF Solutions首席执行官。Erb先生从1997年开始在IntraTherapeutics公司担任裁兼首席执行官公司直到2001年该公司被Sulzer Medica 收购。该公司是一家参与末梢血管支架的研发，生产和销售的医疗器械公司。此前，Erb先生是在 Pfizer公司的一个部门--施耐德全球运营任职副总裁。他从2001年10月开始是SenoRx这家上市公司的董事，直到这家公司被C. R. Bard公司于2010年7月收购。同时在2000年10月，他在CryoCath Technologies这家加拿大上市公司任职董事，直到这家公司在2008年12月被收购。Erb先生目前是Sunshine Heart公司、 Osprey医疗公司以及其他几个私人公司的董事。
- John Erb has served on our Board since April of 2017. Mr. Erb is currently Chairman of the Board for Nuwellis Inc., a global medical device company involved in the treatment of heart failure, and has been in that role since 2016. He also currently serves as Chairman of the Board of Directors for Osprey Medical, a public ASX company. Mr. Erb is co-founder of NuAx, Inc. formerly Cardia Access, Inc., a medical device company involved in developing new devices for the treatment of heart disease. Previously, Mr. Erb served as Chairman of the Board of Directors for Vascular Solution, Inc., a public NASDAQ company, (acquired by Teleflex Incorporated), and was a board member for CryoCath Technologies (acquired by Medtronic in 2008) and SenoRx, Inc. (acquired by CR Bard in 2010). From 2001 through 2006 Mr. Erb was Chief Executive Officer of CHF Solutions, Inc., a medical device company focused on the treatment of congestive heart failure. CHF Solutions, Inc. was acquired by Gambro. From 1997 through 2001 Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents. IntraTherapeutics, Inc. was acquired by Sulzer Medica. Other previous executive experience includes Vice President of Operations for Schneider Worldwide, a division of Pfizer, Inc.; ten years with Johnson & Johnson’s Iolab Division; and the start of his career with American Hospital Supply Corporation. Mr. Erb has a B.S. in Business Administration from California State University, Fullerton.
- Peter Maag
-
Peter Maag自2012年11月起担任CareDx公司董事会成员，自2020年11月起担任CareDx公司执行主席。Maag博士还于2012年10月至2020年11月担任CareDx公司首席执行官，并于2012年10月至2018年11月担任CareDx公司总裁。在加入公司之前，2001年9月至2012年4月，Maag博士在Novartis International AG（一家全球医疗保健公司）担任多个职位，责任越来越大，包括2009年至2012年担任Novartis Diagnostics （Novartis a.g。的业务部门）的全球主管。2006年至2008年，Maag博士担任Novartis Pharma AG在德国的国家总裁，2003年至2005年担任Novartis韩国业务的国家总裁，2001年至2002年担任Novartis A.G。制药部门的战略主管。从1995年到2001年，Maag博士还在McKinsey & Company工作，专注于医疗保健和全球化。除了支持各种医疗保健和科技公司的增长努力外，Maag博士还担任Phoenix Pharma SE的董事会职务，并在华盛顿特区的个性化医疗联盟董事会任职。Maag博士在海德堡大学和伦敦大学学习制药科学，并在德国柏林大学获得博士学位。
Peter Maag,has served as Kyverna Therapeutics, Inc. Chief Executive Officer since October 2022. Dr. Maag is a seasoned global industry executive with a track record of transforming organizations and more than 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining Kyverna, Dr. Maag was Executive Chairman of CareDx, Inc. (Nasdaq: CDNA) from November 2020 to November 2021 and Chief Executive Officer and President of CareDx from October 2012 to November 2020, where he built the company from a small start-up into a public company and industry-leading transplantation company through a series of BD&L and financing transactions. Prior to joining CareDx, Dr. Maag held multiple positions at Novartis with increasing responsibilities. As President, Novartis Diagnostics, he drove growth and innovation in its blood-screening business. Prior to that, he led one of Novartis' key affiliates as country president, Germany, and lived in a dynamically growing market as Country President, Korea. At headquarters in Switzerland, he served as the head of strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise. Prior to joining Novartis, Dr. Maag worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. In addition to supporting various healthcare and tech companies in their growth efforts, he holds board and advisory positions at Phoenix Pharma SE, CareDx, Inc. (Nasdaq: CDNA), and the Personalized Medicine Coalition. He previously served on the board of directors of MiroMatrix Medical Inc. (Nasdaq: MIRO) from June 2021 until it was acquired by United Therapeutics Corporation in December 2023. Dr. Maag received his PhD from the University of Berlin, Germany, and studied pharmaceutical sciences in Heidelberg and London. - Peter Maag自2012年11月起担任CareDx公司董事会成员，自2020年11月起担任CareDx公司执行主席。Maag博士还于2012年10月至2020年11月担任CareDx公司首席执行官，并于2012年10月至2018年11月担任CareDx公司总裁。在加入公司之前，2001年9月至2012年4月，Maag博士在Novartis International AG（一家全球医疗保健公司）担任多个职位，责任越来越大，包括2009年至2012年担任Novartis Diagnostics （Novartis a.g。的业务部门）的全球主管。2006年至2008年，Maag博士担任Novartis Pharma AG在德国的国家总裁，2003年至2005年担任Novartis韩国业务的国家总裁，2001年至2002年担任Novartis A.G。制药部门的战略主管。从1995年到2001年，Maag博士还在McKinsey & Company工作，专注于医疗保健和全球化。除了支持各种医疗保健和科技公司的增长努力外，Maag博士还担任Phoenix Pharma SE的董事会职务，并在华盛顿特区的个性化医疗联盟董事会任职。Maag博士在海德堡大学和伦敦大学学习制药科学，并在德国柏林大学获得博士学位。
- Peter Maag,has served as Kyverna Therapeutics, Inc. Chief Executive Officer since October 2022. Dr. Maag is a seasoned global industry executive with a track record of transforming organizations and more than 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining Kyverna, Dr. Maag was Executive Chairman of CareDx, Inc. (Nasdaq: CDNA) from November 2020 to November 2021 and Chief Executive Officer and President of CareDx from October 2012 to November 2020, where he built the company from a small start-up into a public company and industry-leading transplantation company through a series of BD&L and financing transactions. Prior to joining CareDx, Dr. Maag held multiple positions at Novartis with increasing responsibilities. As President, Novartis Diagnostics, he drove growth and innovation in its blood-screening business. Prior to that, he led one of Novartis' key affiliates as country president, Germany, and lived in a dynamically growing market as Country President, Korea. At headquarters in Switzerland, he served as the head of strategy for Novartis Pharmaceuticals and helped launch the Infectious Diseases franchise. Prior to joining Novartis, Dr. Maag worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. In addition to supporting various healthcare and tech companies in their growth efforts, he holds board and advisory positions at Phoenix Pharma SE, CareDx, Inc. (Nasdaq: CDNA), and the Personalized Medicine Coalition. He previously served on the board of directors of MiroMatrix Medical Inc. (Nasdaq: MIRO) from June 2021 until it was acquired by United Therapeutics Corporation in December 2023. Dr. Maag received his PhD from the University of Berlin, Germany, and studied pharmaceutical sciences in Heidelberg and London.
高管简历
中英对照 | 中文 | 英文- Jeff Ross
杰夫·罗斯（Jeff Ross）自2017年起担任我们的首席执行官，并自2019年10月起担任董事会成员。在担任我们的首席执行官之前，Ross博士于2010年至2017年担任我们的产品开发副总裁。Ross博士在Guidant开始了他的行业生涯，领导着一个新心血管疗法的生物制剂小组。跟随Guidant，他在Athersys工作，协助干细胞技术的商业化和扩展。他随后在SurModics担任生物制剂研究和商业开发总监。Ross博士拥有30多项已发表和发布的专利，以及《自然》和《临床研究杂志》的领先出版物。他拥有明尼苏达大学的生物医学工程硕士学位和分子，细胞和发育生物学博士学位。
Jeff Ross has been our Chief Executive Officer since 2017 and has served on our Board since October of 2019. Prior to serving as our Chief Executive Officer, Dr. Ross was our Vice President of Product Development from 2010 to 2017. Dr. Ross started his industry career at Guidant leading a biologics group for new cardiovascular therapies. Following Guidant, he worked at Athersys assisting with the commercialization and scale up of stem cell technologies. He then served as Director of Research and Commercial Development of Biologics at SurModics. Dr. Ross has over 30 published and issued patents along with leading publications in Nature and the Journal of Clinical Investigation. He holds a M.S. in Biomedical Engineering and a Ph.D. in Molecular, Cellular and Developmental Biology, from the University of Minnesota.- 杰夫·罗斯（Jeff Ross）自2017年起担任我们的首席执行官，并自2019年10月起担任董事会成员。在担任我们的首席执行官之前，Ross博士于2010年至2017年担任我们的产品开发副总裁。Ross博士在Guidant开始了他的行业生涯，领导着一个新心血管疗法的生物制剂小组。跟随Guidant，他在Athersys工作，协助干细胞技术的商业化和扩展。他随后在SurModics担任生物制剂研究和商业开发总监。Ross博士拥有30多项已发表和发布的专利，以及《自然》和《临床研究杂志》的领先出版物。他拥有明尼苏达大学的生物医学工程硕士学位和分子，细胞和发育生物学博士学位。
- Jeff Ross has been our Chief Executive Officer since 2017 and has served on our Board since October of 2019. Prior to serving as our Chief Executive Officer, Dr. Ross was our Vice President of Product Development from 2010 to 2017. Dr. Ross started his industry career at Guidant leading a biologics group for new cardiovascular therapies. Following Guidant, he worked at Athersys assisting with the commercialization and scale up of stem cell technologies. He then served as Director of Research and Commercial Development of Biologics at SurModics. Dr. Ross has over 30 published and issued patents along with leading publications in Nature and the Journal of Clinical Investigation. He holds a M.S. in Biomedical Engineering and a Ph.D. in Molecular, Cellular and Developmental Biology, from the University of Minnesota.
- Brian Niebur
Brian Niebur自2016年以来一直担任我们的首席财务官。加入公司之前，他曾担任EntrPrize Corp.的首席财务官（2002年至2016年）。从2000年到2016年，他曾担任Wyncrest Capital公司（私人风险投资公司）的副总裁兼总会计师，在那里他曾领导各种私人和上市公司的财务部门。Niebur先生拥有明尼苏达大学会计学学士学位，并且是不活跃的注册会计师。
Brian Niebur has been our Chief Financial Officer since 2016. Prior to joining the Company, he was the chief financial officer of Entrprize Corp. from 2002 to 2016. From 2000 to 2016 he served as the vice president and controller of Wyncrest Capital, Inc., a privately-held venture capital firm, where he led the financial departments of various private and publicly-held corporations. Mr. Niebur has a B.A. in Accounting from the University of Minnesota and is a certified public accountant inactive.- Brian Niebur自2016年以来一直担任我们的首席财务官。加入公司之前，他曾担任EntrPrize Corp.的首席财务官（2002年至2016年）。从2000年到2016年，他曾担任Wyncrest Capital公司（私人风险投资公司）的副总裁兼总会计师，在那里他曾领导各种私人和上市公司的财务部门。Niebur先生拥有明尼苏达大学会计学学士学位，并且是不活跃的注册会计师。
- Brian Niebur has been our Chief Financial Officer since 2016. Prior to joining the Company, he was the chief financial officer of Entrprize Corp. from 2002 to 2016. From 2000 to 2016 he served as the vice president and controller of Wyncrest Capital, Inc., a privately-held venture capital firm, where he led the financial departments of various private and publicly-held corporations. Mr. Niebur has a B.A. in Accounting from the University of Minnesota and is a certified public accountant inactive.
- Laji Kattungal
Laji Kattungal于2020年7月加入我们，担任我们的质量副总裁，在生物制药行业拥有20多年的经验。在加入公司之前，Kattungal先生在大型和小型生物技术公司的质量方面担任了越来越重要的职务，包括最近于2019-2020年担任Nuvation Bio质量部门的负责人，并于2018-2019年担任Sanbio质量部门的负责人。在Sanbio，他是实现关键监管里程碑的团队的一员，包括获得SB623的Sakigake，RMAT和Prime状态，SB623是一种基于细胞的研究产品，有望触发大脑的自然再生能力，以恢复失去的运动功能。在Sanbio工作之前，Kattungal先生于2017-2018年在Orexigen Medivation工作，于2013-2017年在Jazz Pharmaceuticals工作，于2010-2012年在Medimmune工作，于2008-2010年在Amgen工作，于2003-2007年在Amgen工作。作为一名经验丰富的质量专业人员，Kattungal先生成功地建立和管理了广泛而强大的质量组织和计划，以维持内部和外部合规性。他为产品开发-Bench上市的所有阶段提供质量指导，包括临床前、早期和晚期临床试验以及生物制药产品的市场推出。Kattungal先生拥有安娜堡密歇根大学的生物学学士学位。
Laji Kattungal joined us as our Vice President of Quality in July of 2020 with over 20 years of experience in the Biopharmaceutical industry. Prior to joining the Company, Mr. Kattungal held positions of increasing responsibilities within Quality in small and large biotech companies, including, most recently, as the leader of the Quality departments at Nuvation Bio from 2019 - 2020 and at Sanbio from 2018-2019. At Sanbio, he was part of the team that enabled key regulatory milestones, including obtaining the Sakigake, RMAT and Prime status for SB 623 a cell-based investigational product which is expected to trigger the brain’s natural regenerative ability to recover lost motor functions. Prior to his work at Sanbio, Mr. Kattungal worked in Quality at Orexigen from 2017 - 2018 Medivation from 2013 - 2017 Jazz Pharmaceuticals from 2010 - 2012 Medimmune from 2008 - 2010 and Amgen from 2003 - 2007. As a seasoned Quality professional, Mr. Kattungal has successfully built and managed wide-ranging and robust Quality organizations and programs for maintaining internal and external compliance. He has provided Quality guidance, for all phases of product development - bench to market, including, preclinical, early and late phase clinical trials and market launch of Biopharmaceutical products. Mr. Kattungal holds a BS in Biology from the University of Michigan in Ann Arbor.- Laji Kattungal于2020年7月加入我们，担任我们的质量副总裁，在生物制药行业拥有20多年的经验。在加入公司之前，Kattungal先生在大型和小型生物技术公司的质量方面担任了越来越重要的职务，包括最近于2019-2020年担任Nuvation Bio质量部门的负责人，并于2018-2019年担任Sanbio质量部门的负责人。在Sanbio，他是实现关键监管里程碑的团队的一员，包括获得SB623的Sakigake，RMAT和Prime状态，SB623是一种基于细胞的研究产品，有望触发大脑的自然再生能力，以恢复失去的运动功能。在Sanbio工作之前，Kattungal先生于2017-2018年在Orexigen Medivation工作，于2013-2017年在Jazz Pharmaceuticals工作，于2010-2012年在Medimmune工作，于2008-2010年在Amgen工作，于2003-2007年在Amgen工作。作为一名经验丰富的质量专业人员，Kattungal先生成功地建立和管理了广泛而强大的质量组织和计划，以维持内部和外部合规性。他为产品开发-Bench上市的所有阶段提供质量指导，包括临床前、早期和晚期临床试验以及生物制药产品的市场推出。Kattungal先生拥有安娜堡密歇根大学的生物学学士学位。
- Laji Kattungal joined us as our Vice President of Quality in July of 2020 with over 20 years of experience in the Biopharmaceutical industry. Prior to joining the Company, Mr. Kattungal held positions of increasing responsibilities within Quality in small and large biotech companies, including, most recently, as the leader of the Quality departments at Nuvation Bio from 2019 - 2020 and at Sanbio from 2018-2019. At Sanbio, he was part of the team that enabled key regulatory milestones, including obtaining the Sakigake, RMAT and Prime status for SB 623 a cell-based investigational product which is expected to trigger the brain’s natural regenerative ability to recover lost motor functions. Prior to his work at Sanbio, Mr. Kattungal worked in Quality at Orexigen from 2017 - 2018 Medivation from 2013 - 2017 Jazz Pharmaceuticals from 2010 - 2012 Medimmune from 2008 - 2010 and Amgen from 2003 - 2007. As a seasoned Quality professional, Mr. Kattungal has successfully built and managed wide-ranging and robust Quality organizations and programs for maintaining internal and external compliance. He has provided Quality guidance, for all phases of product development - bench to market, including, preclinical, early and late phase clinical trials and market launch of Biopharmaceutical products. Mr. Kattungal holds a BS in Biology from the University of Michigan in Ann Arbor.